Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANFLYTA Tablet Post-marketing Surveillance Study
jRCT1080224910Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Overall safety profile and QT interval prolongation. Started Oct 2019; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT1080224910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224910.